Javascript is disabled or is not supported by your browser. Please upgrade your browser or enable Javascript to navigate the interface properly.

Vivo Capital

Latest statistics and disclosures from Vivo Capital's latest quarterly 13F-HR filing:

Top 5 stock holdings are TRVI, PRAX, ERAS, AVBP, ABVX, and represent 34.25% of Vivo Capital's stock portfolio.
Added to shares of these 10 stocks: TENX (+$33M), AVBP (+$28M), ABVX (+$23M), ACHV (+$18M), EDIT (+$12M), Odyssey Therapeutics (+$11M), AURA (+$8.3M), MLTX (+$7.8M), AVTX (+$5.1M), ANRO.
Started 7 new stock positions in EDIT, AURA, INM, Odyssey Therapeutics, AVTX, VALN, ACHV.
Reduced shares in these 10 stocks: ERAS (-$147M), TERN (-$70M), TNGX (-$24M), PRAX (-$23M), MANE (-$19M), COGT (-$16M), SABS (-$16M), DBVT (-$14M), Soleno Therapeutics (-$9.9M), UNCY (-$5.8M).
Sold out of its positions in COGT, CMPS, Soleno Therapeutics, TERN, MANE, VRDN.
Vivo Capital was a net seller of stock by $-198M.
Vivo Capital has $1.1B in assets under management (AUM), dropping by -8.97%.
Central Index Key (CIK): 0001674712

Tip: Access up to 7 years of quarterly data

Positions held by Vivo Capital consolidated in one spreadsheet with up to 7 years of data

Download as csv

Download as Excel

Portfolio Holdings for Vivo Capital

Vivo Capital holds 47 positions in its portfolio as reported in the June 2026 quarterly 13F filing

Company (Ticker)	Portfolio Weight	Valued At	Change in Shares	Share Count	Share Price
Trevi Therapeutics Common (TRVI)	8.7	$95M		5.1M	18.65	View chart
Praxis Precision Medicines Common (PRAX)	8.3	$91M	-20%	271k	334.79	View chart
Erasca Common (ERAS)	6.9	$76M	-66%	4.1M	18.32	View chart
Arrivent BioPharma Common (AVBP)	5.3	$58M	+89%	1.7M	34.74	View chart
Abivax SA - Sponsored Ads (ABVX)	5.0	$55M	+73%	415k	133.26	View chart
Tango Therapeutics Common (TNGX)	3.9	$43M	-35%	1.4M	31.26	View chart
Corvus Pharmaceuticals Common (CRVS)	3.8	$42M		2.8M	14.94	View chart
Bright Minds Biosciences Common (DRUG)	3.6	$39M		557k	70.20	View chart
Sinovac Biotech SHS	3.5	$38M		5.9M	6.47	View chart
Tenax Therapeutics Common (TENX)	3.3	$36M	+1100%	2.5M	14.55	View chart
Aclaris Therapeutics Common (ACRS)	3.2	$35M		6.7M	5.29	View chart
Dyne Therapeutics Common (DYN)	3.2	$35M		1.6M	22.21	View chart
Dianthus Therapeutics Common (DNTH)	3.2	$35M		354k	97.48	View chart
Alto Neuroscience Common (ANRO)	2.9	$32M	+16%	1.2M	26.39	View chart
DBV Technologies SA Sponsored Ads (DBVT)	2.8	$30M	-30%	1.8M	16.40	View chart
SAB Biotherapeutics Common (SABS)	2.6	$29M	-36%	7.3M	3.90	View chart
Moonlake Immunotherapeutics Class A ORD (MLTX)	2.5	$27M	+40%	1.4M	19.47	View chart
LB Pharmaceuticals Common (LBRX)	2.4	$26M		800k	32.45	View chart
Minerva Neurosciences Common (NERV)	2.2	$24M		4.3M	5.55	View chart
Design Therapeutics Common (DSGN)	2.1	$23M		1.6M	14.47	View chart
Oric Pharmaceuticals Common (ORIC)	1.8	$20M		1.8M	10.83	View chart
CAMP4 Therapeutics Corporation Common (CAMP)	1.7	$19M		4.2M	4.37	View chart
Faeth Therapeutics Common (FTH)	1.6	$18M		722k	25.00	View chart
Achieve Life Sciences Common (ACHV)	1.6	$18M	NEW	2.8M	6.53	View chart
Compass Therapeutics Common (CMPX)	1.6	$17M	-18%	7.8M	2.19	View chart
AN2 Therapeutics Common (ANTX)	1.4	$15M		3.2M	4.84	View chart
Editas Medicine Common (EDIT)	1.1	$12M	NEW	3.6M	3.24	View chart
Geron Corp Common (GERN)	1.0	$11M		8.7M	1.28	View chart
Odyssey Therapeutics Common	1.0	$11M	NEW	575k	18.71	View chart
Eupraxia Pharmaceuticals Common (EPRX)	0.8	$8.9M		1.4M	6.61	View chart
Onkure Therapeutics Common (OKUR)	0.8	$8.8M		1.9M	4.56	View chart
Olema Pharmaceuticals Common (OLMA)	0.8	$8.4M		672k	12.51	View chart
Monopar Therapeutics Common (MNPR)	0.8	$8.4M		91k	92.59	View chart
Aura Biosciences Common (AURA)	0.8	$8.3M	NEW	1.2M	7.10	View chart
Surrozen Common (SRZN)	0.6	$6.7M		260k	25.95	View chart
ALX Oncology Holdings Common (ALXO)	0.6	$6.6M		3.2M	2.07	View chart
Satellos Bioscience Common (MSLE)	0.6	$6.3M		814k	7.78	View chart
Avalo Therapeutics Common (AVTX)	0.5	$5.1M	NEW	275k	18.48	View chart
Pepgen Common (PEPG)	0.4	$4.2M		2.3M	1.80	View chart
Valneva SE Sponsored Ads (VALN)	0.4	$4.0M	NEW	763k	5.23	View chart
Sera Prognostics Common (SERA)	0.3	$3.0M		1.7M	1.82	View chart
Unicycive Therapeutics Common (UNCY)	0.2	$2.6M	-69%	550k	4.69	View chart
Instil Bio Common (TIL)	0.2	$2.3M		293k	7.69	View chart
InMed Pharmaceuticals Common (INM)	0.1	$1.2M	NEW	798k	1.55	View chart
Bolt Biotherapeutics Common (BOLT)	0.0	$279k		72k	3.85	View chart
Pasithea Therapeutics Corp Common (KTTA)	0.0	$240k	-77%	466k	0.52	View chart
Precision Biosciences Common (DTIL)	0.0	$37k		4.7k	7.86	View chart

Past Filings by Vivo Capital

SEC 13F filings are viewable for Vivo Capital going back to 2016

Vivo Capital 2026 Q2 filed Aug. 14, 2026
Vivo Capital 2026 Q1 restated filed May 20, 2026
Vivo Capital 2026 Q1 filed May 15, 2026
Vivo Capital 2025 Q4 filed Feb. 13, 2026
Vivo Capital 2025 Q3 filed Nov. 14, 2025
Vivo Capital 2025 Q2 filed Aug. 14, 2025
Vivo Capital 2025 Q1 filed May 12, 2025
Vivo Capital 2024 Q4 filed Feb. 13, 2025
Vivo Capital 2024 Q3 filed Nov. 13, 2024
Vivo Capital 2024 Q2 filed Aug. 14, 2024
Vivo Capital 2024 Q1 filed April 22, 2024
Vivo Capital 2023 Q4 filed Feb. 7, 2024
Vivo Capital 2023 Q3 filed Nov. 8, 2023
Vivo Capital 2023 Q2 filed Aug. 14, 2023
Vivo Capital 2023 Q1 filed May 15, 2023
Vivo Capital 2022 Q4 filed Feb. 13, 2023

View all past filings

Disclaimers: stockzoa.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on stockzoa.com represent a recommendation to purchase or sell a stock. The information on this site is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall stockzoa.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content available on stockzoa.com, or relating to the use of, or inability to use, stockzoa.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

Fund Directory: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X-Z